Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link .

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com .

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com

News Provided by GlobeNewswire via QuoteMedia

abos:us acumen pharmaceuticals inc.base metals investing nasdaq:abos:us Base Metals Investing

ABOS:US

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024
Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024
Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027
Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Vertex Minerals Limited Power-up Gravity Gold Plant at Reward

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce an update on the Reward Gold mine start up, with powering the plant up now completed and mechanical commissioning underway.

The processing facility rebuild, refurbishment and installation has progressed safely, efficiently and to plan, with the focus now turning to dry and wet commissioning of the respective operating circuits.

HIGHLIGHTS

- Vertex power up the newly installed Gravity Gold plant at the Reward Gold Mine.

- The Power generation units have now been installed and plugged into the Gravity plant.

- The plant components are now all installed and connected electrically.

- Completion of the dry stack tailing storage facility and tailings pipework installation.

- The plant can now be started up and mechanically tested and operated.

- Wet commissioning and ore feed commissioning will follow.

- Ore Sorter installation will be a retrofitted in early January

- Commissioning will be with stockpiled gold ore located alongside the gold plant

Vertex's Executive Chairman, Roger Jackson, said: "On time and within budget, the refurbishment and installation activities at the Reward gravity gold processing plant are almost complete with power up testing now underway. Our focus is now switching to dry and wet commissioning in the lead up to first gold next month. This is an exciting milestone for the company given the quality of the plant and the low capex required to get to this stage".

The Reward gold mine is well placed for a simple start -up:

- The new processing plant has been installed adjacent to the underground mine portal (640 Level) and over the existing footprint of the existing plant

- The 640 Level extends into the resource and no stripping required.

- Second egress in place with existing ladder way from 640 Level to surface.

- Some underground fleet and utility services are already owned by Vertex. With new fleet arriving.

*To view photographs, please visit:
https://abnnewswire.net/lnk/B92995G8

About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.

Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less

Osisko Metals Announces Closing of C$107.4 Million "Bought Deal" Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Osisko Metals Incorporated (the " Company " or " Osisko Metals ") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce that it has closed its previously-announced "bought deal" brokered private placement offering (the " Offering ") for aggregate gross proceeds of C$107.4 million, including the partial exercise the option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued an aggregate of (i) 70,326,229 flow-through units of the Company (" FT Units ") consisting of 64,215,117 FT Units at an issue price of C$0.50 per FT Unit and 6,111,112 FT Units at an issue price of C$0.54 per FT Unit, for aggregate gross proceeds of C$35,407,558.98 and (ii) 277,051,466 units of the Company (" HD Units ") at a price of C$0.26 per HD Unit, for aggregate gross proceeds of C$72,033,381.16.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Falco Announces Election of Directors and Closing of Its Senior Debt Transactions

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") announces that the five (5) nominees listed in the management information circular dated November 4, 2024, were elected as directors of Falco.

Detailed results of the vote for the election of directors held at the annual and special meeting of shareholders on December 10, 2024, are set out below:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals, Inc.
Condensed Balance Sheets
(in thousands, except share and per share data)
	March 31,			December 31,
		2024			2023
	(unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	46,930		$	66,886
Marketable securities, short-term		205,582			176,636
Prepaid expenses and other current assets		3,319			3,093
Total current assets		255,831			246,615
Marketable securities, long-term		44,108			62,553
Right-of-use asset		353			381
Restricted cash		234			233
Property and equipment, net		117			122
Other assets		324			221
Total assets	$	300,967		$	310,125
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$	3,079		$	1,379
Accrued clinical trial expenses		2,367			4,387
Accrued expenses and other current liabilities		2,905			6,339
Finance lease liability, short-term		-			756
Operating lease liability, short-term		121			110
Total current liabilities		8,472			12,971
Operating lease liability, long-term		252			284
Debt, long-term		30,209			29,897
Total liabilities		38,933			43,152
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023		-			-
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		6			6
Additional paid-in capital		499,843			489,453
Accumulated deficit		(237,671	)		(222,798	)
Accumulated other comprehensive income (loss)		(144	)		312
Total stockholders' equity		262,034			266,973
Total liabilities and stockholders' equity	$	300,967		$	310,125


Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
	Three Months Ended March 31,
		2024			2023

Operating expenses
Research and development	$	12,449		$	8,713
General and administrative		5,325			4,422
Total operating expenses		17,774			13,135
Loss from operations		(17,774	)		(13,135	)
Other income (expense)
Interest income		4,005			1,832
Interest expense		(1,000	)		-
Change in fair value of embedded derivatives		(50	)		-
Other expense, net		(54	)		(4	)
Total other income		2,901			1,828
Net loss		(14,873	)		(11,307	)
Other comprehensive gain (loss)
Unrealized gain (loss) on marketable securities		(456	)		227
Comprehensive loss	$	(15,329	)	$	(11,080	)
Net loss per common share, basic and diluted	$	(0.25	)	$	(0.28	)
Weighted-average shares outstanding, basic and diluted		59,812,000			41,025,062

Condensed Statements of Cash Flows
(in thousands)
(unaudited)
	Three Months Ended March 31,
		2024			2023

Cash flows from operating activities
Net loss	$	(14,873	)	$	(11,307	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		16			14
Stock-based compensation expense		2,484			1,390
Amortization of premiums and accretion of discounts on marketable securities, net		(1,763	)		(334	)
Change in fair value of embedded derivatives		50			-
Amortization of right-of-use asset		28			38
Realized gain on marketable securities		(2	)		-
Non-cash interest expense		268			-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(226	)		(899	)
Other assets		35			(44	)
Accounts payable		1,700			(878	)
Accrued clinical trial expenses		(2,020	)		2,486
Accrued expenses and other current liabilities		(3,512	)		(38	)
Finance lease liability		(23	)		-
Operating lease liability		(21	)		(603	)
Net cash used in operating activities		(17,859	)		(10,175	)
Cash flows from investing activities
Purchases of marketable securities		(45,292	)		(52,131	)
Proceeds from maturities and sales of marketable securities		36,100			10,204
Purchases of property and equipment		(11	)		-
Net cash used in investing activities		(9,203	)		(41,927	)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs		7,938			-
Payment for financing lease		(739	)		-
Payments for deferred offering costs		(60	)		-
Repurchase of common shares to pay employee withholding taxes		(32	)		-
Net cash provided by financing activities		7,107			-
Net change in cash and cash equivalents and restricted cash		(19,955	)		(52,102	)
Cash and cash equivalents and restricted cash at the beginning of the period		67,119			130,101
Cash and cash equivalents and restricted cash at the end of the period	$	47,164		$	77,999

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
Mann West
MAN24-42	9.0	345.2	336.2	0.24	0.012	0.004	0.007	0.20	6.40	0.068
and	371.7	402.0	30.3	0.19	0.010	0.003	0.005	0.38	6.82	0.053
MAN24-61	17.8	374.3	356.5	0.28	0.012	0.033	0.017	0.26	5.98	0.133
including	75.0	112.5	37.5	0.52	0.013	0.107	0.058	0.14	5.80	0.203
MAN24-70	18.0	501.0	483.0	0.24	0.011	0.007	0.008	0.27	6.12	0.067
including	144.0	172.5	28.5	0.29	0.011	0.007	0.007	0.14	5.52	0.076
MAN24-73	74.2	500.4	426.2	0.25	0.012	0.009	0.009	0.25	6.30	0.061
MAN24-74	7.9	278.5	270.6	0.19	0.014	0.027	0.016	0.40	7.40	0.057
including	25.5	31.5	6.0	0.31	0.013	0.028	0.013	0.82	6.67	0.125
and	318.0	402.0	84.0	0.24	0.013	0.003	0.005	0.16	7.45	0.026
MAN24-76	12.6	495.0	482.4	0.26	0.011	0.011	0.010	0.16	5.95	0.042
including	81.0	117.0	36.0	0.29	0.012	0.036	0.014	0.16	6.11	0.089
and	162.0	196.5	34.5	0.31	0.011	0.010	0.012	0.13	5.24	0.024
MAN24-78	19.4	402.0	382.6	0.24	0.013	0.012	0.010	0.38	6.54	0.053
including	261.0	294.0	33.0	0.30	0.013	0.031	0.021	0.52	6.67	0.100
including	274.5	282.0	7.5	0.41	0.015	0.057	0.027	0.72	6.95	0.178
MAN24-82	22.0	481.5	459.5	0.21	0.012	0.017	0.016	0.37	6.76	0.047
including	61.5	360.0	298.5	0.25	0.012	0.019	0.013	0.35	6.17	0.050
including	255.0	277.5	22.5	0.30	0.013	0.025	0.014	0.58	5.91	0.069
MAN24-83	6.0	403.0	397.0	0.21	0.013	0.016	0.011	0.58	7.43	0.087
including	144.0	195.9	51.9	0.27	0.014	0.030	0.024	0.68	7.87	0.064
and	305.5	336.0	30.5	0.27	0.013	0.019	0.009	0.60	6.30	0.080
MAN24-85	69.0	493.0	424.0	0.25	0.012	0.012	0.008	0.26	6.25	0.042
MAN24-86	14.2	462.0	447.8	0.23	0.012	0.006	0.006	0.41	6.33	0.027
MAN24-89	99.0	191.2	92.2	0.22	0.012	0.013	0.009	0.47	6.71	0.042
and	210.6	428.9	218.3	0.24	0.012	0.009	0.008	0.35	6.31	0.053
including	386.0	395.0	9.0	0.35	0.013	0.054	0.020	0.75	6.45	0.120
MAN24-92	27.4	426.9	399.5	0.25	0.012	0.016	0.008	0.39	6.27	0.046
including	267.0	286.5	19.5	0.34	0.015	0.083	0.034	0.66	6.57	0.114
and	324.0	349.5	25.5	0.30	0.012	0.037	0.015	0.57	6.29	0.125
and	433.6	501.0	67.4	0.20	0.013	0.013	0.021	0.50	7.35	0.047
MAN24-93	18.0	391.0	373.0	0.24	0.012	0.009	0.007	0.34	6.43	0.039
and	406.8	470.0	63.2	0.16	0.011	0.005	0.004	0.36	7.34	0.031
MAN24-94	102.0	501.0	399.0	0.24	0.012	0.012	0.009	0.39	6.50	0.039
including	400.5	415.5	15.0	0.30	0.011	0.044	0.021	0.57	6.57	0.083
MAN24-97	18.0	360.0	342.0	0.21	0.013	0.015	0.009	0.37	6.63	0.053
and	406.5	501.0	94.5	0.23	0.012	0.003	0.003	0.39	7.10	0.021

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
Mann South
MAN24-66	39.0	139.5	100.5	0.23	0.013	0.003	0.003	0.29	8.03	0.070
and	187.5	402.0	214.5	0.18	0.013	0.003	0.004	0.43	6.61	0.019
MAN24-72	54.5	501.0	446.5	0.20	0.013	0.005	0.006	0.43	6.80	0.019
MAN24-75	16.9	420.0	403.1	0.24	0.010	0.018	0.006	0.30	7.92	0.051
MAN24-77	39.0	46.0	7.0	0.44	0.017	0.051	0.126	0.57	9.28	0.036
and	60.0	448.5	388.5	0.14	0.014	0.019	0.013	0.41	6.96	0.016
MAN24-81	44.3	552.0	507.7	0.24	0.011	0.003	0.003	0.38	7.55	0.056
MAN24-84	28.4	501.0	472.6	0.24	0.011	0.003	0.003	0.42	7.70	0.057
MAN24-90	49.3	501.0	451.7	0.23	0.012	0.004	0.005	0.37	6.33	0.015
MAN24-91	49.0	323.3	274.3	0.17	0.013	0.004	0.004	0.44	6.93	0.043
and	338.7	483.0	144.3	0.22	0.012	0.003	0.003	0.37	6.13	0.021
MAN24-99	51.3	402.0	350.7	0.17	0.013	0.004	0.012	0.46	6.60	0.011
MAN24-100C	21.0	112.4	91.4	0.16	0.014	0.036	0.096	0.37	7.46	0.010
and	131.0	172.0	41.0	0.22	0.012	0.010	0.010	0.61	5.69	0.031
and	340.5	378.4	37.9	0.19	0.013	0.005	0.003	0.56	6.52	0.027
MAN24-103	34.0	402.0	368	0.24	0.012	0.027	0.003	0.36	7.67	0.016

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
Mann Central
MAN24-41	111.9	153.0	41.1	0.18	0.012	0.004	0.005	0.52	7.42	0.096
MAN24-48	75.0	402.0	327.0	0.21	0.011	0.005	0.006	0.29	6.58	0.084
including	148.5	157.5	9.0	0.35	0.015	0.019	0.008	0.14	8.73	0.199
MAN24-64	14.3	48.5	34.2	0.22	0.012	0.005	0.008	0.18	6.66	0.584
and	55.8	334.9	279.1	0.19	0.012	0.014	0.017	0.40	7.00	0.053
MAN24-68	366.0	406.0	40.0	0.24	0.012	0.003	0.006	0.15	8.77	0.028

Hole ID	From (m)	To (m)	Length (m)	Pt+Pd (g/t)	Pd g/t)	Pt (g/t)	Ni (%)	Co (%)	Cr (%)	Fe (%)	S (%)
Mann West
MAN24-74	278.5	309.0	30.5	0.48	0.28	0.20	0.037	0.007	0.394	5.763	0.011
MAN24-82	481.5	501.0	19.5	0.52	0.28	0.24	0.024	0.007	0.324	5.919	0.014
MAN24-97	378.5	400.5	22	0.40	0.23	0.17	0.040	0.008	0.360	5.179	0.018
Mann South
MAN24-66	160.0	180.7	20.7	0.49	0.33	0.16	0.026	0.005	0.362	3.957	0.017
MAN24-72	44.0	54.5	10.5	0.37	0.12	0.24	0.037	0.009	0.313	5.849	0.011
MAN24-77	37.0	60.0	23	0.55	0.16	0.39	0.216	0.012	0.409	6.386	0.016
and	444.0	457.5	13.5	0.34	0.10	0.24	0.098	0.013	0.596	6.776	0.015
and	492.0	529.5	37.5	0.35	0.14	0.21	0.055	0.008	0.499	5.450	0.008
MAN24-100C	75.0	91.5	16.5	0.53	0.11	0.42	0.131	0.013	0.314	6.600	0.011
and	112.4	131.0	18.6	0.82	0.31	0.51	0.064	0.009	0.474	5.288	0.006
and	172.0	196.5	24.5	0.77	0.32	0.46	0.048	0.009	0.518	5.375	0.007
Mann Central
MAN24-64	334.9	351.5	16.6	0.52	0.33	0.19	0.043	0.008	0.371	5.291	0.019

Hole ID	Easting ( mE)	Northing ( mN)	Azimuth (⁰)	Dip ( ⁰)	Length (m)
MANN WEST
MAN24-42	496024	5411983	35	-50	402
MAN24-61	496859	5412156	215	-50	402
MAN24-70	496492	5412296	215	-50	501
MAN24-73	496604	5412445	215	-50	500
MAN24-74	495656	5412189	215	-85	402
MAN24-76	496560	5412057	215	-50	495
MAN24-78	495969	5412226	215	-85	402
MAN24-82	495980	5412379	215	-50	501
MAN24-83	496980	5412318	215	-50	450
MAN24-85	496493	5412451	215	-50	493
MAN24-86	496442	5411894	215	-50	489
MAN24-89	496297	5412494	215	-50	495
MAN24-92	496177	5412332	215	-50	501
MAN24-93	496373	5412289	215	-50	471
MAN24-94	496098	5412537	215	-50	501
MAN24-97	495765	5412456	220	-50	501
MANN SOUTH
MAN24-66	503460	5408195	35	-50	402
MAN24-72	503650	5408420	35	-50	501
MAN24-75	502081	5405730	55	-50	420
MAN24-77	502345	5405431	50	-50	540
MAN24-81	503460	5408195	220	-50	552
MAN24-84	502406	5408781	35	-50	501
MAN24-90	503140	5409045	35	-50	501
MAN24-91	503358	5408852	35	-50	483
MAN24-99	502349	5405667	55	-50	402
MAN24-100C	502169	5405546	55	-50	378
MAN24-103	501960	5405890	55	-50	402
MANN CENTRAL
MAN24-41	498466	5410751	145	-55	153
MAN24-48	498066	5410676	180	-50	402
MAN24-64	498058	5410435	180	-50	406
MAN24-68	497871	5410435	180	-50	402

*ITEM N* ^o 1 Nominee	Votes Cast FOR	Percentage (%) of Votes Cast FOR	Votes AGAINST	Percentage (%) of Votes AGAINST
Mario Caron	117,113,938	99.637	426,433	0.363
Alexander Dann	109,446,599	93.114	8,093,772	6.886
Paola Farnesi	117,103,520	99.628	436,851	0.372
Luc Lessard	117,473,626	99.943	66,745	0.057
Chantal Sorel	113,119,685	96.239	4,420,686	3.761

*ITEM N* ^o 2	*Votes cast* *FOR*	Percentage (%) of Votes Cast FOR	Votes WITHHELD	Percentage (%) of Votes WITHHELD
Appointment and Remuneration of Auditor	122,925,232	99.311	852,564	0.689

*ITEM N* ^o 3	Votes Cast FOR	Percentage (%) of Votes Cast FOR	Votes AGAINST	Percentage (%) of Votes AGAINST
Ordinary resolution to approve the LTIP	101,288,332	86.173	16,252,039	13.827

*ITEM N* ^o 4	Votes Cast FOR	Percentage (%) of Votes Cast FOR	Votes AGAINST	Percentage (%) of Votes AGAINST
Ordinary resolution of disinterested shareholders to approve the amendment of the Osisko Loan and the issuance of the Osisko Warrants	70,256,713	99.844	109,858	0.156

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Latest News

Latest Press Releases

Related News

TOP STOCKS